Literature DB >> 25274890

Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease.

Anna-Maria Hoffmann-Vold1, Ragnar Gunnarsson2, Torhild Garen2, Øyvind Midtvedt2, Øyvind Molberg2.   

Abstract

OBJECTIVE: To assess the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for Systemic Sclerosis (SSc) on defined subgroups of SSc and in mixed connective tissue disease (MCTD) as an SSc-related disease.
METHODS: The 2013 ACR/EULAR criteria were assessed in 425 consecutive patients suspected to have SSc and seen at Oslo University Hospital, and in the nationwide Norwegian MCTD cohort (n = 178). In the SSc group, 239/425 patients had disease duration < 3 years (in 82 of these, duration was < 1 yr). Patients were subgrouped as limited SSc (n = 294), diffuse SSc (n = 97), SSc sine scleroderma (n = 10), and early SSc (prescleroderma; n = 24). Item data were complete, except nailfold capillaroscopy and telangiectasia results, missing in the MCTD cohort.
RESULTS: The 2013 ACR/EULAR SSc criteria were met by 409/425 patients (96%) in the SSc group. For comparison, only 75% (293/391) met the 1980 ACR SSc classification criteria. All the novel items in the 2013 ACR/EULAR criteria were frequent in the SSc cohort. Considering that there were missing data on 2 items, 10% (18/178) of the MCTD cohort met the 2013 ACR/EULAR criteria, giving an estimated specificity of 90% toward this SSc-like disorder.
CONCLUSION: In our large and representative group of consecutive patients with SSc, the 2013 ACR/EULAR SSc criteria were more sensitive than the ACR 1980 criteria. However, the new criteria did not completely segregate SSc from MCTD, making specificity a potential issue.

Entities:  

Keywords:  AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; EPIDEMIOLOGY; SYSTEMIC SCLEROSIS

Mesh:

Year:  2014        PMID: 25274890     DOI: 10.3899/jrheum.140047

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  New ACR EULAR guidelines for systemic sclerosis classification.

Authors:  Sindhu R Johnson
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

2.  The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters.

Authors:  J N Kimmel; D A Carlson; M Hinchcliff; M A Carns; K A Aren; J Lee; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2016-02-27       Impact factor: 3.598

3.  Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

Authors:  Farley Carvalho Araújo; Cíntia Zumstein Camargo; Cristiane Kayser
Journal:  Rheumatol Int       Date:  2017-08-17       Impact factor: 2.631

Review 4.  Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.

Authors:  Silvia Bellando-Randone; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2017-09-18       Impact factor: 4.592

5.  The diagnostic value of trichoscopy in systemic sclerosis.

Authors:  Małgorzata Kwiatkowska; Adriana Rakowska; Irena Walecka; Lidia Rudnicka
Journal:  J Dermatol Case Rep       Date:  2016-11-13

Review 6.  The use and abuse of diagnostic/classification criteria.

Authors:  Rayford R June; Rohit Aggarwal
Journal:  Best Pract Res Clin Rheumatol       Date:  2015-05-23       Impact factor: 4.098

7.  Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018): A Population-based Study.

Authors:  Caitrin M Coffey; Yasser A Radwan; Avneek S Sandhu; Cynthia S Crowson; Philippe R Bauer; Eric L Matteson; Ashima Makol
Journal:  J Scleroderma Relat Disord       Date:  2021-06-23

8.  Performance of the new American College of Rheumatology classification criteria in Turkish systemic sclerosis patients: a multicenter study.

Authors:  Omer Nuri Pamuk; Mehmet Ali Balcı; Ahmet Mesut Onat; Orhan Zengin; Necati Cakır; Bunyamin Kısacık
Journal:  Clin Rheumatol       Date:  2015-12-07       Impact factor: 2.980

9.  OX40L blockade protects against inflammation-driven fibrosis.

Authors:  Muriel Elhai; Jérôme Avouac; Anna Maria Hoffmann-Vold; Nadira Ruzehaji; Olivia Amiar; Barbara Ruiz; Hassina Brahiti; Matthieu Ponsoye; Maxime Fréchet; Anne Burgevin; Sonia Pezet; Jérémy Sadoine; Thomas Guilbert; Carole Nicco; Hisaya Akiba; Vigo Heissmeyer; Arun Subramaniam; Robert Resnick; Øyvind Molberg; André Kahan; Gilles Chiocchia; Yannick Allanore
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-13       Impact factor: 11.205

Review 10.  Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis.

Authors:  Yulei Hao; Meiying Xin; Shuang Wang; Di Ma; Jiachun Feng
Journal:  Neurol Sci       Date:  2019-05-21       Impact factor: 3.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.